MRUS Merus N.V.

11.54
+0.18  (+2%)
Previous Close 11.36
Open 11.38
Price To Book 2.74
Market Cap 262545005
Shares 22,750,867
Volume 15,566
Short Ratio
Av. Daily Volume 48,663

NewsSee all news

  1. Merus to Participate in Guggenheim Healthcare Talks Idea Forum
  2. Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
  3. Johnson & Johnson Is Selling These 2 Biotech Stocks
  4. Amarin Down on Lower '19 View, Posts Preliminary '18 Results
  5. Merus Announces IND Clearance for MCLA-145

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607175
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604965
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19588046
  4. 6-K/A [Amend] - Report of foreign issuer [Rules 13a-16 and 15d-16] 19571548
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19534785

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 update due 2H 2019.
MCLA-128
Breast cancer - HER2-positive MBC and ER+/HER2-low MBC
Noted December 27, 2018 that NSCLC cohort enrolment is ongoing but will discontinue endometrial and ovarian cohorts.
MCLA-128
Gastric cancer, non-small cell lung cancer
Phase 1 readouts due 2H 2019.
MCLA-117
Acute Myeloid Leukemia
Phase 1 emerging data due YE 2019.
MCLA-158
Colorectal cancer

Latest News

  1. Merus to Participate in Guggenheim Healthcare Talks Idea Forum
  2. Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
  3. Johnson & Johnson Is Selling These 2 Biotech Stocks
  4. Amarin Down on Lower '19 View, Posts Preliminary '18 Results
  5. Merus Announces IND Clearance for MCLA-145
  6. ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals
  7. Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China
  8. The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO
  9. Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update
  10. Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals
  11. Is Merus N.V. (MRUS) Going to Burn These Hedge Funds?
  12. Is Merus NV (NASDAQ:MRUS) A Financially Sound Company?
  13. Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607175
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604965
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19588046
  4. 6-K/A [Amend] - Report of foreign issuer [Rules 13a-16 and 15d-16] 19571548
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19534785
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 19506890
  7. D - Notice of Exempt Offering of Securities 19501794
  8. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19501696
  9. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181255194
  10. F-1 - Registration statement for certain foreign private issuers 181254942